Study Finds Certain Autoantibodies May Serve as Biomarkers for Lupus Nephritis

Several autoantibodies are associated with lupus nephritis (LN). Early detection and treatment is very important. In a new study, researchers examined autoantibodies and their association with LN classification and treatment response. They found several non-invasive biomarkers of proliferative LN, which may help inform treatment decisions over time. 

A group of 279 racially-diverse people with systemic lupus erythematosus (SLE) and proteinuria underwent kidney biopsies and had diagnostic testing for LN. Of the group, 268 were diagnosed with LN and 11 had no evidence of LN. Researchers followed the group along with 22 healthy controls and performed lab tests at baseline, 3 months, 6 months, 9 months and 12 months. During this period, each individual continued on their particular medication regimen. 

The researchers categorized autobody concentrations as low, moderate or high and found certain autoantibody profiles significantly associated with distinct biological features of LN. Higher levels of certain autoantibodies were linked to more severe kidney damage and poorer outcomes. Additionally, changes over time in autoantibody levels offered insight into LN disease progression and response to treatment. This study highlights the potential of several autoantibodies as biomarkers for LN and treatment response which can help improve patient care and quality of life. 

Jill Buyon, MD and Michelle Petri, MD, who are both former Evelyn V. Hess, MD, MACP, MACR Award Recipients, were co-authors of this study. Learn more about lupus nephritis.

Read the study